SCHEMBL449624

SCHEMBL449624

CCOC(=O)C1CCc2ccc(Br)cc2C1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.57
KMT2A Q03164 5/20 0.57
ALDH1A1 P00352 4/20 0.57
KDM4E B2RXH2 2/20 0.57
MAPT P10636 2/20 0.57
GAA P10253 1/20 0.57
HPGD P15428 1/20 0.57
HSD17B10 Q99714 1/20 0.57
TDP2 O95551 1/20 0.44
MAPK1 P28482 1/20 0.40
ACHE P22303 1/20 0.40
PTGS2 P35354 1/20 0.40
BRD4 O60885 1/20 0.39
CYP4F2 P78329 1/20 0.39
CYP4A11 Q02928 1/20 0.39
TSHR P16473 2/20 0.38
LMNA P02545 2/20 0.38
POLB P06746 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30438181 0.90 MEN1 (0.53) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL19900425 0.90 MEN1 (0.53) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL30759564 0.88 MAPT (0.45) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL27120697 0.88 MAPT (0.45) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL28579183 0.85 TDP1 (0.40) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL23460007 0.85 MEN1 (0.57) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL23459934 0.85 ALDH1A1 (0.57) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL8435265 0.84 ALDH1A1 (0.56) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL22070885 0.81 GAA (0.53) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL947365 0.81 ALDH1A1 (0.55) MEN1KMT2AALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065195-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. 2012-03-15 US disclosed
WO-2011123674-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES ARRAY BIOPHARMA INC. (US) 2011-10-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065195-A1 COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES APP, BACE1, PSEN1 MEN1 1819/4885KMT2A 3951/4885ALDH1A1 878/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.